The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy

@inproceedings{Wu2014ThePI,
  title={The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy},
  author={Chung-Pu Wu and Suresh V. Ambudkar},
  booktitle={Acta pharmaceutica Sinica. B},
  year={2014}
}
Melanoma is the most serious type of skin cancer and one of the most common cancers in the world. Advanced melanoma is often resistant to conventional therapies and has high potential for metastasis and low survival rates. Vemurafenib is a small molecule inhibitor of the BRAF serine-threonine kinase recently approved by the United States Food and Drug Administration to treat patients with metastatic and unresectable melanomas that carry an activating BRAF (V600E) mutation. Many clinical trials… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 90 references

Vemurafenib ( PL 4032 , Zelboraf s ) , a BRAF inhibitor , modulates ABCB 1 - , ABCG 2 - , and ABCC 10 - mediated multidrug resistance

  • SG Vispute, JJ Chen, YL Sun, KS Sodani, S Singh, Y Pan
  • J Cancer Res Updates
  • 2013

Similar Papers

Loading similar papers…